Earnings · China A-shares
Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A (688266) earnings
Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A published its Q3 report on 2026-10-30: net profit +783.25% year on year, +604.75% excluding one-off items. Wave Radar's earnings-quality score is 82 of 100 (Sound). The stock moved +11.70% in the 3 trading days after the report.
- Report
- Q3 report
- Published
- 2026-10-30
- Period end
- 2026-09-30
- Net profit YoY
- +783.25%
- Excl. one-offs YoY
- +604.75%
- Net profit QoQ
- -123.58%
- Result
- Great
- Quality score
- 82
- Quality
- Sound
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | +4.36% | — |
| 3 days | +11.70% | — |
| 7 days | +9.82% | — |
| 14 days | -5.25% | — |
Report history
Over the last 8 reports, net profit grew year on year in 6 of them. The stock rose in the 3 trading days after 4 of 7 reports (average +2.83%).
| Report | Published | Net profit | Profit YoY | Excl. one-offs YoY | Revenue YoY | EPS | ROE | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3 report | 2026-10-31 | ¥638.27M | +783.25% | +604.75% | +158.91% | 2.41 | 45.60% | +11.70% | — | — |
| 2026 interim report | 2026-08-01 | ¥640.01M | +979.09% | +700.66% | +220.88% | 2.42 | 45.70% | -9.62% | -12.64% | -11.24% |
| 2026 Q1 report | 2026-04-29 | ¥632.61M | +2338.37% | +1362.40% | +440.07% | 2.39 | 45.29% | +6.64% | -6.58% | -7.52% |
| 2025 annual report | 2026-03-28 | -¥162.95M | -18.22% | -15.60% | +52.07% | -0.62 | -13.96% | +3.39% | -0.09% | -9.45% |
| 2025 Q3 report | 2025-10-31 | -¥93.42M | +4.58% | -15.42% | +54.49% | -0.35 | -7.78% | +15.92% | +21.15% | +25.84% |
| 2025 interim report | 2025-08-23 | -¥72.80M | -9.42% | -41.83% | +56.07% | -0.28 | -5.98% | -6.05% | -7.15% | -12.02% |
| 2025 Q1 report | 2025-04-19 | -¥28.26M | +28.45% | -17.83% | +54.87% | -0.11 | -2.28% | -2.14% | +14.54% | +11.59% |
| 2024 annual report | 2025-04-19 | -¥137.83M | +50.52% | +50.92% | +37.91% | -0.52 | -9.42% | -2.14% | +14.54% | +11.59% |
The last 8 reports. Net profit is attributable to shareholders and year-to-date (a Q3 report covers the first nine months). Moves count trading days from the first tradeable session after publication; "30d vs index" is the excess return over CSI 300.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.